ストックスクリーナーアプリを入手
5.2429
6.79%
-0.3571
前日終値:
$5.60
開ける：
$5.5
24時間の取引高:
731.65K
Relative Volume:
0.77
時価総額：
$215.68M
収益：
$134.48M
当期純損益:
$-38.94M
株価収益率:
-5.4992
EPS:
-0.9534
ネットキャッシュフロー:
$-19.34M
1週間 パフォーマンス:
+8.30%
1か月 パフォーマンス:
+4.40%
6か月 パフォーマンス:
-45.74%
1年 パフォーマンス:
-58.00%
1日の値動き範囲:
$5.175
$5.74
1週間の範囲:
$4.85
$5.76
52週間の値動き範囲:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Compare RXST vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
5.21 | 232.23M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
97.53 | 166.17B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.63 | 125.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.44 | 106.49B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.99 | 67.09B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.35 | 54.34B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | 開始されました | William Blair | Mkt Perform |
| 2025-07-15 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | ダウングレード | Jefferies | Buy → Hold |
| 2025-07-09 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-09 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-09 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 開始されました | Piper Sandler | Neutral |
| 2025-04-09 | ダウングレード | UBS | Buy → Neutral |
| 2025-04-04 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2025-04-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-12-20 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-10-29 | 開始されました | Jefferies | Buy |
| 2024-08-20 | 繰り返されました | Needham | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-05-07 | 繰り返されました | BTIG Research | Buy |
| 2023-12-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 開始されました | Stifel | Buy |
| 2023-12-04 | 開始されました | Morgan Stanley | Overweight |
| 2023-04-13 | 開始されました | Oppenheimer | Outperform |
| 2022-12-12 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 開始されました | Needham | Buy |
すべてを表示
Rxsight Inc (RXST) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST - The National Law Review
RxSight, Inc.(NasdaqGM: RXST) dropped from Russell 2500 Growth Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) added to Russell Microcap Value Benchmark Index - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) added to Russell 2000 Value Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) dropped from Russell 2000 Growth Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) dropped from Russell 3000E Growth Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) added to Russell Microcap Index - marketscreener.com
Class Action Alert: Levi & Korsinsky Reminds RxSight, Inc. (RXST) Investors of September 22, 2025 Deadline - The National Law Review
Liquidity Mapping Around (RXST) Price Events - Stock Traders Daily
RXST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
RXST Stockholders Have Opportunity to Lead RxSight, Inc. Class Ac - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - The National Law Review
Lost Money on RxSight, Inc. (RXST)? Contact Levi & Korsinsky Before September 22, 2025 to Join Class Action - The National Law Review
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
RXST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RXST Forecast — Price Target — Prediction for 2027 - TradingView
RxSight, Inc. Actuals & Estimates (NASDAQ:RXST) - TradingView
RxSight, Inc. Actuals & Estimates (BOATS:RXST) - TradingView
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RXST SEC FilingsRxsight, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RxSight (RXST) director receives 37,037 restricted stock units in equity grant - Stock Titan
RxSight (RXST) director awarded 37,037 RSUs in equity compensation grant - Stock Titan
RxSight (RXST) director Shweta Maniar receives 37,037 RSU award - Stock Titan
Tamara Fountain at RxSight (RXST) receives 37,037-share RSU award - Stock Titan
RxSight (RXST) director William J. Link granted 37,037-share stock award - Stock Titan
RxSight (RXST) director Corley Jesse Anderson granted 37,037 RSUs - Stock Titan
RxSight (RXST) director granted 30,864 RSUs vesting by next meeting - Stock Titan
RxSight (RXST) director receives 37,037 RSUs vesting by next stockholder meeting - Stock Titan
RxSight (RXST) director receives 37,037 RSUs, now directly holds 85,183 shares - Stock Titan
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rxsight Inc (RXST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RxSight Stockholders Back Leadership at 2026 Annual Meeting - The Globe and Mail
Rxsight Inc (RXST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rxsight Inc (RXST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rxsight Inc (RXST) Institutional Confidence - TradingKey
Rxsight Inc (RXST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rxsight Inc (RXST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RxSight (RXST) investors re-elect board, approve pay and ratify Ernst & Young - Stock Titan
RxSight Inc Stock (US78419L1008): Valuation Focus After Strong Run In Eye Technology - AD HOC NEWS
RxSight, Inc. Hits 52-Week Low of $4.58 Amidst 92.2% Decline - MarketsMojo
RxSight, Inc. Stock Plummets to New 52-Week Low of $4.49 - MarketsMojo
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates - MSN
RxSight Inc. (RXST) Falters Near Support: Testing Key Levels After 1.96% DeclineDark Pool Sentiment - newsline.com
Understanding Momentum Shifts in (RXST) - Stock Traders Daily
RxSight, Inc. Hits 52-Week Low at $5.31 Amid Ongoing Struggles - MarketsMojo
RxSight, Inc. Hits 52-Week Low at USD 4.93 Amidst Ongoing Struggles - MarketsMojo
RxSight Inc. (RXST) Slides 3% as Stock Struggles Below Key Resistance at $5.03Put Wall - newsline.com
RxSight Inc. (RXST) Q1 2026 Earnings: EPS Miss Weighs on Shares Amid Operating ChallengesProfitability Analysis - newsline.com
RXST Technical Analysis & Stock Price Forecast - Intellectia AI
RxSight Inc stock (US78419L1008): Nasdaq-listed eye-care specialist in focus after recent price weak - AD HOC NEWS
Rxsight Inc (RXST) 財務データ
収益
当期純利益
現金流量
EPS
Rxsight Inc (RXST) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Goldshleger Ilya | See remarks |
Sep 25 '25 |
Option Exercise |
4.27 |
23,445 |
99,998 |
65,691 |
1.55%
大文字化:
|
ボリューム (24 時間):